INCY Chart

1 Month

	Date	Diff
	2023-03-31	+1.73 %
Shares of Incyte (INCY) rose by 1.73% due to positive news from Forte Biosciences, which announced that its product candidate FB-102 is progressing towards the clinic in late 2023 or early 2024 and holds significant potential in a variety of autoimmune disease indications with large markets.
	2023-03-29	+1.18 %
Innovent Biologics, which has strategic collaborations with companies such as Incyte, Sanofi, and Eli Lilly, announced their 2022 annual results with a diversified commercial portfolio and further improved commercial operational efficiency, and their stock went up 1.18% as a result. Innovent Biologics, a biopharmaceutical company that develops and commercializes medicines, has reported its 2022 annual results and major business updates, including an increased commercial portfolio, pipeline expansion, R&D innovation, and strategic collaborations, which have led to a 3.4% increase in product revenue, benefiting Innovent's broader patient groups; the positive news has led to the 1.18% increase in the Incyte(INCY) stock. Innovent Biologics has announced its annual results for 2022 and major business updates, revealing that it has built a strong and diverse pipeline with over 30 innovative drug candidates, eight of which are already approved, and its strategical position in several key non-oncology areas brings the company another important pillar of their future business growth, which has caused an increase in INCY stock.
	2023-03-27	+0.83 %
The stock of Incyte (Nasdaq:INCY) went up by 0.83% after the company received approval from the Japanese Ministry of Health, Labour and Welfare for its selective fibroblast growth factor receptor inhibitor, Pemazyre, for the treatment of myeloid/lymphoid neoplasms with FGFR1 fusion, which is a rare group of aggressive cancers characterized by an over-production of bone tissue. Incyte Corporation's stock went up by 0.83% last night, despite the U.S. FDA's failure to approve the extended-release version of its cancer drug Jakafi, which caused the stock to drop 5.3% due to concerns over potential competition.
	2023-03-24	-2.81 %
Incyte stock went down by 2.81% as FDA rejected the proposed once-daily version of Jakafi tablets, the company's blockbuster blood-cancer drug, for treating certain types of myelofibrosis, polycythemia vera, and graft-versus-host disease. Incyte's stock went down by 2.81% after the FDA rejected the extended-release version of its drug, Jakafi. Incyte's stock dropped about 4% after the pharmaceutical company announced that the FDA would not approve its application for a new blood cancer drug tablet in its current form.
	2023-03-22	-1.67 %
Incyte's stock was down 1.67% after the FDA approved Zynyz, a humanized monoclonal antibody targeting the programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). The company plans to continue studying the potential of Zynyz in additional tumor types and in combination with other Incyte pipeline compounds. Incyte (INCY) stock went down by 1.67% after MacroGenics (MGNX) announced that they will receive a $15 million milestone payment from Incyte following FDA approval of ZYNYZ™ (retifanlimab-dlwr), a humanized monoclonal antibody for the treatment of Merkel cell carcinoma, that was developed by MacroGenics and licensed to Incyte. Incyte Corporation's stock price decreased by 1% after the biopharmaceutical company announced that the FDA has given accelerated approval for its monoclonal antibody, Zynyz, for use in Merkel cell carcinoma (MCC) patients, although one brokerage firm sees the commercial opportunity for Zynyz as somewhat limited due to competition from Merk's Keytruda and Merk KGaA and Pfizer's Bavencio drugs, which are already approved to treat MCC.
	2023-03-21	-0.98 %
Innovent Biologics announced that clinical data from multiple trials in relation to TYVYT (sintilimab injection), Pemazyre (pemigatinib), and IBI351 (KRASG12C inhibitor) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, which might have caused a drop of Incyte(INCY) stock by 0.98%. Innovent Biologics announced that clinical data from several trials related to its drugs, including Sintilimab, Pemazyre, and IBI351, will be presented at the American Association for Cancer Research Annual Meeting in Orlando in April; however, shares of Incyte (INCY), which collaborates with Innovent, fell 0.98%.
	2023-03-17	-0.47 %
The article is not about Incyte (INCY) stock but instead provides a transcript of a conference call discussing the progress of Agenus' deep immuno-oncology pipeline, which reportedly includes promising results from botensilimab, a clinical stage multifunctional Fc-enhanced CTLA-4 antibody, which has produced durable objective responses in nine cold and/or treatment resistant cancers, though it is unclear why this caused Incyte's stock to go down.
	2023-03-15	-2.07 %
MorphoSys AG reports its financial results for Q4 and full year 2022, with CEO Jean-Paul Kress emphasizing the company's commitment to developing novel therapies for oncology; Incyte (INCY) stock may have gone down due to the mention of lower mid-single to low-double-digit royalties on program net sales, as well as 17% workforce reduction at MorphoSys headquarters to optimize cost structure.
	2023-03-14	+1.12 %
Incyte (INCY) stock was 1.12% up last night, and the article is not related to the stock's performance, but instead discusses Agenus' progress in developing botensilimab, a clinical-stage antibody designed to treat cold and treatment-resistant cancers. Incyte stock went up by 1.12% after announcing that multiple abstracts from across its oncology portfolio will be presented during the American Association for Cancer Research (AACR) Annual Meeting 2023, and that data on pemigatinib, as well as five-year results from the L-MIND study of tafasitamab, will be highlighted in presentations. Incyte (INCY) stock rose by 1.12% amid expectations that the company will settle its litigation with Sun Pharma over patents for Ruxolitinib and Deuruxolitinib, which could result in a royalty payment until the expiry of the patent.
	2023-03-07	-1.94 %
Incyte (INCY) stock went down by 1.94% as Caris Life Sciences announced a strategic research partnership with the company to improve precision medicine approaches across two therapeutic programs initially, with the option for Incyte to expand to four total programs.
	2023-03-06	-2.2 %
Incyte's shares fell 2.2% on 5 March after it announced it would discontinue its Limber-304 study for the treatment of myelofibrosis as the phase three will likely not meet the primary endpoint. Incyte's stock (NASDAQ: INCY) fell by 2.2% in response to it announcing the presentation of multiple abstracts featuring data from its dermatology portfolio at the 2023 American Academy of Dermatology Annual Meeting, with new data from the Phase 3 TRuE-V clinical trial revealing the durability and long-term response of Opzelura cream, LTD.
	2023-02-08	-0.57 %
The company's earnings fell in the latest quarter, weighed down by higher expenses.
	2023-02-07	-4.03 %
The stock price of incyte(INCY) goes down because the company released weak financial guidance and forward-looking statements. The stock of incyte(INCY) tumbled Tuesday after topping expectations in the December-quarter earnings report, while Haemonetics(HAE) followed suit, diving despite a beat-and-raise. An earnings report from Incyte sent the stock skidding, as it reported worse-than-expected results, sending it below a buy point.
	2023-01-24	+0.19 %
Incyte is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. This makes incyte stock bullish because it means that the company has a chance to become successful and make lots of money. Agenus (NASDAQ:AGEN) released data that is very encouraging and, if approved, could spark significant growth for the company's stock price.
	2023-01-19	+1.96 %
Incyte's stock goes up because it hit a key performance benchmark and its Relative Strength Rating jumped into the 80-plus percentile.
	2023-01-17	+0.53 %
Incyte's fourth quarter and year-end 2022 financial results conference call is scheduled for 8am on 7/31/2023.
	2023-01-12	+0.97 %
David Gryska has been appointed to the Forte Biosciences Board of Directors and he has extensive experience in the biotechnology and pharmaceutical industries. This strengthens the board and will help the company advance its product candidates.
	2023-01-09	-2.53 %
The stock of incyte(INCY) goes down because its revenue and profit is stagnant, while its competitors are reporting better results.
	2023-01-05	+1.37 %
MorphoSys AG reduced its financial liability from the collaboration with Incyte and credited finance income accordingly. MorphoSys AG reports preliminary 2022 Monjuvi U.S. net product sales and provides 2023 financial guidance. This moves the company closer to satisfying its debt with Incyte.
	2023-01-04	-0.59 %
Innovent Biologics, Inc. (Incyte) is expected to report financial results for the fourth quarter and full year 2019 on January 9, 2023. The stock price of Incyte declined as investors anticipate disappointing results.
	2023-01-03	-0.96 %
CIPhotosIntroduction I have always maintained that Cathie Wood and ARK Investment Management LLC - perhaps best known for its ARK Innovation ETF (ARKK) - do excellent research that goes much deeper than the quarterly outlook myopia present in Wall Street. If one combines the very important temporal drivers with the strong fundamental assessment of specialist deep research firms such as Ark Invest, I suspect one can do quite well in their investments. Indeed, that is what I attempt to do here as we look at the burgeoning genomics sector: The ARK Genomic Revolution ETF (BATS:ARKG) tracks the technological and scientific developments
	2022-11-21	+1.24 %